ASGCT 2026: Gene Therapy Advances from Circio, Encoded & More

Key Takeaways

• The ASGCT Annual Meeting 2026 will showcase the latest advancements in gene and cell therapies.
• Presentations from companies like Circio Holding, Encoded Therapeutics, MiNK Therapeutics, and Calidi Biotherapeutics will highlight preclinical and early clinical data.
• Circio's circVec platform demonstrates enhanced gene expression in preclinical models.
• Encoded Therapeutics will present clinical data on ETX101 for Dravet syndrome at a Presidential Symposium.

The ASGCT (American Society of Gene & Cell Therapy) Annual Meeting 2026, scheduled for May 11–15, 2026, in Boston, MA, will feature presentations and discussions on the latest developments in gene and cell therapies. Several companies, including Circio Holding, Encoded Therapeutics, MiNK Therapeutics, and Calidi Biotherapeutics, are expected to present new data.

The ASGCT Annual Meeting is a key event for researchers, clinicians, and industry professionals in the gene and cell therapy field. It provides a platform to share the latest scientific breakthroughs, clinical trial results, and technological advancements. The 2026 meeting promises to be particularly exciting, with several companies presenting potentially groundbreaking data.

Circio Holding: circVec Platform

Circio Holding will present an oral presentation validating its circVec technology. Preclinical data has demonstrated enhanced gene expression with circVec, showing up to 50-fold increase in the eye and 40-fold in the heart. The full scope of the presentation will be disclosed after April 13, 2026.

Encoded Therapeutics: ETX101 for Dravet Syndrome

Encoded Therapeutics will feature clinical data on ETX101, a gene therapy for Dravet syndrome, in a Presidential Symposium. The presentation will focus on the impact of ETX101 on this severe genetic epilepsy. Clinical data from an ongoing study will be presented.

MiNK Therapeutics: agenT-797

MiNK Therapeutics will present a poster on agenT-797 (allogeneic iNKT cell therapy). The poster, titled *AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS*, will be presented by Terese C. Hammond, MD. The presentation will cover the therapy's adaptive immune modulation in cancer and acute respiratory distress syndrome (ARDS).

Calidi Biotherapeutics: RedTail Platform

Calidi Biotherapeutics will deliver a speaker presentation highlighting the capabilities of its RedTail platform. Antonio F. Santidrian, PhD, Chief Scientific Officer at Calidi, will present on May 14, 2026, focusing on the platform's ability to avoid immune clearance and deliver genetic medicines systemically to distal disease sites.

The presentations at ASGCT 2026 are expected to provide valuable insights into the potential of gene and cell therapies for a range of diseases. Investors and industry analysts will be closely watching the data presented, as it could have significant implications for the future of these companies and the field as a whole.

The release of detailed abstract information in mid-April 2026 will provide a more complete picture of the data to be presented at ASGCT 2026. The field will be watching for further updates on these and other promising gene and cell therapy programs.

Frequently Asked Questions

• What is the ASGCT Annual Meeting?

  The ASGCT Annual Meeting is a major conference for researchers, clinicians, and industry professionals in the gene and cell therapy field.

• When and where will ASGCT 2026 be held?

  ASGCT 2026 will take place May 11–15, 2026, in Boston, MA.

• Which companies are presenting data at ASGCT 2026?

  Confirmed presentations include Circio Holding, Encoded Therapeutics, MiNK Therapeutics, and Calidi Biotherapeutics.

• What is Encoded Therapeutics presenting on?

  Encoded Therapeutics will present clinical data on ETX101 for Dravet syndrome in a Presidential Symposium.

• When will more details about the presentations be available?

  Detailed abstract information, including session times, will be released in mid-April 2026.

References

• Circio Holding ASGCT Announcement
• MiNK Therapeutics agenT-797 ASGCT Abstract
• FirstWord Pharma ASGCT Preview
• MiNK Therapeutics ASGCT Presentation Details
• Encoded Therapeutics ETX101 ASGCT Announcement
• Calidi Biotherapeutics RedTail ASGCT Presentation

Related coverage

• $2M Gene Therapy Cures Need a Financing Model
• Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
• Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know